<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156360</url>
  </required_header>
  <id_info>
    <org_study_id>YT2019-001</org_study_id>
    <nct_id>NCT04156360</nct_id>
  </id_info>
  <brief_title>Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer</brief_title>
  <official_title>Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detetct Circulating tumor cells(CTCs) and Cancer Associated
      Macrophage-Like cells (CAMLs) in patients with pulmonary nodules using a novel microfluidic
      CTC-detection system. Then construct an early diagnostic model for lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients found pulmonary nodules by CT screening will be enrolled in this study
      prospectively. CTCs and CAMLs both are cancer specific biomarkers found in the peripheral
      blood of patients with solid tumors including lung cancer. Through detecting CTCs and CAMLs
      in healthy volunteers and patients with pulmonary nodules who undergo biopsy, determine the
      cut-off value of the test. Further analysis of the test specificity and sensitivity, and on
      this basis construct an early diagnostic model for lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of prevalence of CTCs and CAMLs in patients with pulmonary nodules</measure>
    <time_frame>12 months</time_frame>
    <description>The number of CTCs and CAMLs will be detected in the peripheral blood of patients with pulmonary nodules using a novel microfluidic CTC-detection system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of optimal cut-off values for screening Lung Cancer paitents</measure>
    <time_frame>6 months</time_frame>
    <description>The optimal cut-off values will be determined by the ROC analyses.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy</condition>
  <condition>Pulmonary Nodule</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients With Pulmonary Nodule</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with pulmonary nodules diagnosed by chest CT or low-dose computed tomography
        (LDCT) scans
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male, 18 years of age or older

          -  Pulmonary nodules diagnosed by chest CT or low-dose computed tomography (LDCT) scans

        Exclusion Criteria:

          -  Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yayi He, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yayi He, MD, PHD</last_name>
    <phone>+862165115006</phone>
    <email>2250601@qq.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Caicun Zhou</investigator_full_name>
    <investigator_title>Director Head of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

